Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

BMC Res Notes. 2021 Nov 14;14(1):413. doi: 10.1186/s13104-021-05832-0.

Abstract

Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs.

Results: There were 279 M. tuberculosis isolates from the two cohorts (2004-2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0-0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0-0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.

Keywords: Drug resistance; Levofloxacin; Moxifloxacin; Ofloxacin.

MeSH terms

  • Antitubercular Agents / pharmacology
  • Drug Resistance, Bacterial
  • Fluoroquinolones / pharmacology
  • Humans
  • Levofloxacin
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mycobacterium tuberculosis*
  • Peru / epidemiology
  • Pharmaceutical Preparations*
  • Tuberculosis*
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / epidemiology

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • Pharmaceutical Preparations
  • Levofloxacin
  • Moxifloxacin